BioHarvest Sciences (BHST) Canaccord Genuity’s 45th Annual Growth Conference summary

Company overview and technology

• Global leader in plant cell biology with unique IP and patents, operating for 17 years.

• Two business units: direct-to-consumer and CDMO, both leveraging proprietary technology.

• Technology solves consistency, economic viability, and patentability issues in plant-derived compounds.

• Platform enables mirroring, magnifying, and multiplying phytonutrients at industrial scale, non-GMO.

• Manufacturing facility produces 25 tons annually, with $5M CapEx yielding $65M revenue potential.

Direct-to-consumer business

• VINIA red grape cell superfood is the flagship product, with $34M run rate and 60% gross margin.

• 90% of sales are subscription-based, with rapid cash turnaround and high customer ratings.

• Clinical trials show significant arterial dilation and improved blood flow, supporting health claims.

• Product line expanded to coffee, tea, and upcoming hydration solutions, all leveraging core technology.

• Pricing held steady for four years, with margin growth driven by scale and technology maturity.

CDMO business and partnerships

• CDMO unit launched 16 months ago, now with three major contracts and 70%+ gross margin.

• Business model includes discovery, development, and royalty-based manufacturing partnerships.

• Notable partners include a NASDAQ-listed pharma company, Tate & Lyle for sweeteners, and a fragrance entrepreneur.

• Pipeline includes pharma, food, nutraceutical, and cosmeceutical projects, with a 40% project success rate.

• Royalty-based relationships expected to drive long-term high-margin revenue.